ArticleJCO precision oncology2018
Circulating
Article in JCO precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Reliability of BRAF mutation detection using plasma sample: A systematic review and meta-analysisMedicine · 2021Pooled it
- Improving Detection Efficiency of FNAC and BRAF V600E Mutation in Thyroid Nodules Using Pipette Mixing: A Retrospective Study.Diagnostic cytopathology · 2026Article
- Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center.Endocrine · 2026Article
- Tumor-informed liquid biopsy for monitoring thyroid cancer: a proof-of-concept study.European thyroid journal · 2026Article
- Emerging liquid biopsy markers in thyroid cancer: from isolation technologies to clinical translation.Frontiers in endocrinology · 2026Review
- Targeted therapy for pediatric glioma: RAF(t)ing in the molecular era.World journal of pediatrics : WJP · 2025Review
- Anticancer drug therapy for anaplastic thyroid cancer.European thyroid journal · 2025Review
- BRAF V600E Mutation in Ganglioglioma: Impact on Epileptogenicity and Implications for Surgical Strategy.European journal of neurology · 2025Article
- Nomogram model based on ultrasonography and contrast-enhanced CT for predicting BRAFFrontiers in endocrinology · 2025Article
- Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer.Exploration of targeted anti-tumor therapy · 2025Review
- Detection of theJournal of clinical medicine · 2024Review
- An Overview on Prevalence and Detection Approaches of BRAF V600E Mutation in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta-Analysis.Iranian journal of public health · 2024Review
- Review
- Review
- Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.Thyroid : official journal of the American Thyroid Association · 2021Article
- Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer.International journal of molecular sciences · 2021Review
- Molecular-Driven Therapy in Advanced Thyroid Cancer.Current treatment options in oncology · 2021Review
- Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.Endocrine reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 4 countries.
Funding
Abstract
Purpose: Anaplastic thyroid cancer (ATC) is a deadly form of thyroid cancer. Materials and Methods: The ddPCR assay was evaluated for its sensitivity, specificity for detection of Results: Forty-four patients with ATC who were tested for the Conclusion: cfDNA detection by ddPCR is highly sensitive, specific, and concordant with mutation status on ATC tumors. ddPCR also can be used for monitoring cfDNA levels in conjunction with imaging scans in patients with ATC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.